Dupilumab is the first biologic agent approved for treatment of moderate to severe atopic dermatitis (AD). Phase 3 clinical trials have shown the efficacy and safety in AD children. However, real-world evidence is still scarce. Thirty-nine pediatric patients with uncontrolled AD who regularly recei...
Children with severe atopic dermatitis (AD) have a multidimensional disease burden. Here we assess the clinically meaningful improvements in AD signs, symp
参考文献: [1] AS P, EL S, EC S, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2022 Sep 17;4...
A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and UpAdolescentsAdultsAtopic dermatitisChildrenDupilumabEfficacySafetyAtopic dermatitis (AD) is a chronic pruritic skin disease that can have a profound negative impact on ...
10.Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, doub...
PARIS — For adolescents with moderate to severeatopic dermatitis,dupilumabsignificantly improves the signs and symptoms of the disease, including itch, new data from a phase 3 study show. And the drug, administered without topical steroids, was well tolerated in the study population, said Eric Sim...
The New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® 300 mg weekly experienced significant improvements in signs and symptoms of eos...
Eight phase 3 clinical studies evaluating dupilumab exposure among patients with atopic dermatitis were what the analysis was based upon. These data included findings from the LIBERTY AD SOLO 1, SOLO 2, CHRONOS, PEDS, ADOL, PRESCHOOL Part B, OLE, and PED-OLE studies. ...
Bansal A. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021 Mar;22(2):243-255. doi: 10.1007/s40257-020-00583-3. Epub 2021 Mar 3. PMID: 33655423; PMCID: PMC79...
approval, we are proud that Dupixent has the potential to redefine the treatment landscape in yet another disease, as a first-in-class therapy demonstrating unprecedented improvements on exacerbations and lung function, as well as improving health-related quality of life across two lar...